Document Detail


Imatinib induces hypothyroidism in patients receiving levothyroxine.
MedLine Citation:
PMID:  16198662     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Interactions of imatinib with other drugs have been scarcely reported. We report a previously unknown effect of imatinib on levothyroxine therapy. Eleven patients (1 with gastrointestinal stromal tumor and 10 with medullary thyroid carcinoma) received imatinib. Eight had undergone thyroidectomy and used levothyroxine, and 3 had the thyroid in situ. Thyroid function was measured before, during, and within 2 weeks after any change in either imatinib or levothyroxine dosage. We observed symptoms of hypothyroidism in all patients who had undergone thyroidectomy, whereas patients with the thyroid in situ remained clinically and biochemically euthyroid. On average, thyrotropin (INN, thyrotrophin) levels increased to 384% +/- 228% of the upper limit in patients after thyroidectomy, whereas free thyroxine (fT4) and free tri-iodothyronine (fT3) values remained within the reference range (59% +/- 17% of the upper limit for fT4 and 63% +/- 4% of the upper limit for fT3). Clinicians should be aware that hypothyroid subjects receiving imatinib have a high likelihood for increased levothyroxine replacement and should be closely monitored for elevations in thyrotropin indicating worsening hypothyroidism.
Authors:
Jan Willem B de Groot; Bernard A Zonnenberg; John T M Plukker; Winette T A van Der Graaf; Thera P Links
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  78     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-03     Completed Date:  2005-11-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  433-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Endocrinology, University Medical Centre Groningen, Groningen, and Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents / adverse effects*,  pharmacology
Carcinoma, Medullary / drug therapy,  surgery
Drug Synergism
Female
Gastrointestinal Stromal Tumors / drug therapy
Humans
Hypothyroidism / chemically induced*
Male
Middle Aged
Piperazines / adverse effects*,  pharmacology
Pyrimidines / adverse effects*,  pharmacology
Thyroid Neoplasms / drug therapy,  surgery
Thyroidectomy
Thyrotropin / blood
Thyroxine / adverse effects*,  blood,  pharmacokinetics
Triiodothyronine / blood
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib; 6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-...
Next Document:  Removal of Pb from a calcareous soil during EDTA-enhanced electrokinetic extraction.